Abstract
Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having numerous effects and functions. The use of on demand PDE5 inhibitors (-Is) for the treatment of erectile dysfunction (ED) has recently obtained approval for chronic daily dosing for the same indication. There are published data supporting the use of PDE5-Is for the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Additional reports suggest benefit by these agents in patients with chronic heart failure, pulmonary hypertension, essential hypertension, and for the treatment of ischemia. Various central nervous system disorders have been described as targets by PDE5-Is. Sildenafil may have a potential therapeutic indication as a cognitive enhancer in age-related cerebral conditions. There is preclinical evidence for further investigation of the use of PDE5A -Is to improve recovery of cerebral function in humans after stroke by enhancing angiogenesis, neurogenesis and improving neurologic function. Sildenafil delays intestinal ulceration by an increase in the secretion of mucus/fluid and a decrease in hypermotility, and has a protective effect in reducing gastric damage. Larger scale, well designed clinical trials are needed to ascertain the safety, efficacy and cost-effectiveness of PDE5-Is in the future treatment of both urologic and non-urologic diseases. In this review, potential applications of PDE5-Is on urologic, cardiovascular, gastrointestinal, and central nervous system disorders will be updated.
Keywords: Phoshodiesterase enzyme, sildenafil, stroke, cardiovascular disease, pulmonary hypertension, priapism, erectile dysfunction (ED), hypermotility, ischemia, central nervous system disorders.
Current Pharmaceutical Design
Title:PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Volume: 18 Issue: 34
Author(s): Serap Gur, Philip J. Kadowitz, Ege Can Serefoglu and Wayne J.G. Hellstrom
Affiliation:
Keywords: Phoshodiesterase enzyme, sildenafil, stroke, cardiovascular disease, pulmonary hypertension, priapism, erectile dysfunction (ED), hypermotility, ischemia, central nervous system disorders.
Abstract: Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having numerous effects and functions. The use of on demand PDE5 inhibitors (-Is) for the treatment of erectile dysfunction (ED) has recently obtained approval for chronic daily dosing for the same indication. There are published data supporting the use of PDE5-Is for the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Additional reports suggest benefit by these agents in patients with chronic heart failure, pulmonary hypertension, essential hypertension, and for the treatment of ischemia. Various central nervous system disorders have been described as targets by PDE5-Is. Sildenafil may have a potential therapeutic indication as a cognitive enhancer in age-related cerebral conditions. There is preclinical evidence for further investigation of the use of PDE5A -Is to improve recovery of cerebral function in humans after stroke by enhancing angiogenesis, neurogenesis and improving neurologic function. Sildenafil delays intestinal ulceration by an increase in the secretion of mucus/fluid and a decrease in hypermotility, and has a protective effect in reducing gastric damage. Larger scale, well designed clinical trials are needed to ascertain the safety, efficacy and cost-effectiveness of PDE5-Is in the future treatment of both urologic and non-urologic diseases. In this review, potential applications of PDE5-Is on urologic, cardiovascular, gastrointestinal, and central nervous system disorders will be updated.
Export Options
About this article
Cite this article as:
Gur Serap, J. Kadowitz Philip, Can Serefoglu Ege and J.G. Hellstrom Wayne, PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update, Current Pharmaceutical Design 2012; 18 (34) . https://dx.doi.org/10.2174/138161212803307554
DOI https://dx.doi.org/10.2174/138161212803307554 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Managing Obesity in Patients with Mental Illness: A literature Review and Implication for Clinical Practice
Current Psychiatry Reviews Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone
Current Pharmaceutical Design Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Role of Oxidative Stress in Polycystic Ovary Syndrome
Current Women`s Health Reviews Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Effects of Benzodiazepine and Pilocarpine on Rat Parotid Glands: Histomorphometric And Sialometric Study
Medicinal Chemistry Editorial [Hot Topic: Metabolic Syndrome in an Asian Chinese Population and Agents and Targets for Cardiovascular Protection (Guest Editors: M.L. Fung and T.M. Wong)]
Cardiovascular & Hematological Disorders-Drug Targets Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design A Retrospective Study of Drug Induced Cutaneous Adverse Reactions (CADR) in Patients Attending a Tertiary Care Hospital
Current Drug Safety DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Blood Pressure and Childhood Obesity
Current Hypertension Reviews Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Patent Selections
Recent Patents on Biotechnology Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews